Latest Breaking News On - Therapeutics advances - Page 1 : comparemela.com

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Cheng liTherapeutics advancesClinical stageBacillus calmette guRactigen therapeutics

Thermosome Appoints Dr Frank Hermann, MD, as Chief Medical Officer and Adds Prof Alessandro Gronchi, MD, to Clinical Advisory Board

Thermosome Appoints Dr Frank Hermann, MD, as Chief Medical Officer and Adds Prof Alessandro Gronchi, MD, to Clinical Advisory Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Thermosome gmbLudger wess ines regina buthFrank hermannPlanegg martinsriedAlessandro gronchiPascal schweizerKlaus fischerBristol myers squibbAustralasian retroperitoneal sarcoma working groupUniversity hospital giessenBone sarcoma groupClinical development oncology at biontechSarcoma serviceClinical development at catalym gmbJohannes gutenberg university mainzEuropean organization for research

Allterum Therapeutics completes Series Seed offering, builds team with addition of Philip Breitfeld as Chief Medical Officer

Allterum Therapeutics completes Series Seed offering, builds team with addition of Philip Breitfeld as Chief Medical Officer News provided by Share this article Share this article HOUSTON, Dec. 17, 2020 /PRNewswire/ Allterum Therapeutics, Inc. completed its $1.8 million Series Seed offering to members of the FanninDirect SM investor group. Allterum is developing a novel immunotherapy for treatment of IL7R-expressing cancers, including difficult to treat cases of pediatric acute lymphoblastic leukemia (ALL), a program which has received both Orphan Drug and Rare Pediatric Disease Designations from FDA. The company will use the proceeds for its pre-clinical antibody manufacturing and toxicology work and to continue to build the management team.

United statesSerena migginsPhilipp breitfeldProduct developmentNational cancer instituteEric schafer baylor college of medicineTherapeutic centers of excellenceAllterum therapeutics incCancer prevention research institute of texasAllterum therapeuticsSeries seedOrphan drugRare pediatric disease designationsGlobal vice presidentTherapeutic centersChief medical